Inhibiting the cell division regulator Polo-like kinase 1 destroys dormant acute myeloid leukemia stem cells. Standard chemotherapy targets rapidly multiplying cancer cells, leaving resting stem cells untouched to drive disease relapse. Blocking this kinase disrupts internal cargo trafficking along cellular scaffolding, causing the resting stem cells to die without ever entering division.
Section 08
Clinical Medicine
Evidence that reaches the bedside, including trials, drugs, diagnostics, surgery, and devices.
3 entries
Synthetic messenger RNA produces up to twice as much protein when only half of its uridine bases are replaced with 5-methoxyuridine instead of full chemical substitution. Clinical therapies traditionally replace every single uridine unit with modified molecules to prevent immune destruction, assuming complete substitution is mandatory. Swapping only a fraction of the bases shields the genetic strand from immune detection while keeping the RNA structure intact for protein synthesis.
Researchers identified a receptor protein called NLRX1 as the primary regulator of the mitochondrial permeability transition pore. Scientists previously believed pore blockers acted primarily through cyclophilin D or unidentified pathways, but NLRX1 controls channel opening independently of that known factor. The protein sits in the mitochondria and physically links to channel components to dictate when calcium triggers the pore to open.